Targeting CDK7 in oncology: The avenue forward

Area of Science:

• Molecular Biology
• Cancer Research
• Drug Discovery

Background:

• Cyclin-dependent kinase (CDK) 7 regulates fundamental biological processes like cell cycle progression and gene transcription.
• Aberrant CDK7 activity is implicated in tumorigenesis, making it a potential therapeutic target in oncology.
• A prevailing belief that CDK7 is essential for normal cell function has tempered enthusiasm for CDK7-targeted cancer therapies.

Purpose of the Study:

• To comprehensively review the role of CDK7 across various cancers (pan-cancer) by integrating gene information and clinical data.
• To discuss recent advancements in CDK7 protein structure and its functional mechanisms.
• To evaluate CDK7 as a viable target for developing novel cancer therapeutics.

Main Methods:

• Combined analysis of comprehensive gene information.
• Review of preclinical and clinical research findings on CDK7 in cancer.
• Discussion of recent structural biology data and mechanistic studies of CDK7.

Main Results:

• This review provides the first integrated analysis of CDK7's role in pan-cancers.
• Evidence suggests CDK7 plays pivotal roles in tumor development and progression.
• Recent structural and mechanistic insights are summarized, supporting structure-based drug design.

Conclusions:

• CDK7's critical role in diverse cancers challenges the notion of its indispensability in normal cells.
• Targeting CDK7 presents a viable strategy for cancer therapy.
• Structure-based drug discovery approaches hold promise for developing effective CDK7 inhibitors.